PyrotInib in combination with Capecitabine for trasTUzumab-REsistant, HER2-positive advanced breast cancer (PICTURE): a multicenter phase 2 trial

被引：0
|
作者：
Hu, Xichun
Cao, Jun
Teng, Yue'e
Li, Hui-Ping
Zhang, Lili
Ouyang, Quchang
Xie, Weimin
Pan, Yueyin
Song, Zhenchuan
Ling, Xiaoling
Wu, Xiaohong
Xu, Jingwei
Li, Li
Ren, Liping
Wang, Hong
Zhou, Dongxian
Luo, Jing
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-P4-01-43
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P4-01-43
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial
    Cao, Jun
    Teng, Yuee
    Li, Huiping
    Zhang, Lili
    Ouyang, Quchang
    Xie, Weimin
    Pan, Yueyin
    Song, Zhenchuan
    Ling, Xiaoling
    Wu, Xiaohong
    Xu, Jingwei
    Li, Li
    Ren, Liping
    Wang, Hong
    Zhou, Dongxian
    Luo, Jing
    Hu, Xichun
    BMC MEDICINE, 2023, 21 (01)
  • [2] Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer (PICTURE): a single-arm, multicenter phase 2 trial
    Jun Cao
    Yuee Teng
    Huiping Li
    Lili Zhang
    Quchang Ouyang
    Weimin Xie
    Yueyin Pan
    Zhenchuan Song
    Xiaoling Ling
    Xiaohong Wu
    Jingwei Xu
    Li Li
    Liping Ren
    Hong Wang
    Dongxian Zhou
    Jing Luo
    Xichun Hu
    BMC Medicine, 21
  • [3] Pyrotinib plus capecitabine for trastuzumab-resistant, HER2-positive advanced breast cancer: Updated survival results from the phase II PICTURE trial
    Hu, X.
    Cao, J.
    Teng, Y.
    Li, H.
    Zhang, L.
    Ouyang, Q.
    Xie, W.
    Pan, Y.
    Song, Z.
    Ling, X.
    Wu, X.
    Xu, J.
    Li, L.
    Ren, L.
    Wang, H.
    Zhou, D.
    Luo, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S360 - S361
  • [4] Pyrotinib plus capecitabine for HER2-positive, trastuzumab-resistant metastatic breast cancer: A pooled analysis of three randomized controlled trials.
    Jiang, Zefei
    Xu, Binghe
    Yan, Min
    Ouyang, Quchang
    Hu, Xi-Chun
    Li, Wei
    Feng, Ji Feng
    Zhang, Qingyuan
    Tong, Zhongsheng
    Yan, Ping
    Zhu, Xiaoyu
    Rong, Shangyi
    Zou, Jianjun
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [5] Combination of pyrotinib with trastuzumab, taxanes and platinum as neoadjuvant therapy in patients with HER2-positive early or locally advanced breast cancer: a multicenter phase II trial
    Zhou, Hao
    Wang, Lei
    Wang, Lei
    Guo, Zhaoji
    CANCER RESEARCH, 2023, 83 (05)
  • [6] PIKHER2: A phase IB study evaluating buparlisib in combination with lapatinib in trastuzumab-resistant HER2-positive advanced breast cancer
    Guerin, Mathilde
    Rezai, Keyvan
    Isambert, Nicolas
    Campone, Mario
    Autret, Aurelie
    Pakradouni, Jihane
    Provansal, Magali
    Camerlo, Jacques
    Sabatier, Renaud
    Bertucci, Francois
    Charafe-Jauffret, Emmanuelle
    Hervieu, Alice
    Extra, Jean-Marc
    Viens, Patrice
    Lokiec, Francois
    Boher, Jean-Marie
    Goncalves, Anthony
    EUROPEAN JOURNAL OF CANCER, 2017, 86 : 28 - 36
  • [7] Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
    Mateus de Oliveira Taveira
    Sheida Nabavi
    Yuker Wang
    Peter Tonellato
    Francisco J. Esteva
    Lewis C. Cantley
    Gerburg M. Wulf
    Journal of Cancer Research and Clinical Oncology, 2017, 143 : 1255 - 1262
  • [8] Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
    Taveira, Mateus de Oliveira
    Nabavi, Sheida
    Wang, Yuker
    Tonellato, Peter
    Esteva, Francisco J.
    Cantley, Lewis C.
    Wulf, Gerburg M.
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2017, 143 (07) : 1255 - 1262
  • [9] Dual targeted therapy with pyrotinib and trastuzumab for HER2-positive advanced colorectal cancer: A phase 2 trial
    Fu, Xianhua
    Ying, Jieer
    Yang, Liu
    Fang, Weijia
    Han, Weidong
    Hu, Hanguang
    Zhang, Suzhan
    Yuan, Ying
    CANCER SCIENCE, 2023, 114 (03) : 1067 - 1074
  • [10] Clinical observation of lapatinib versus continued use of trastuzumab for trastuzumab-resistant HER2-positive advanced breast cancer
    Yin, Yongmei
    Li, Wei
    Huang, Xiang
    Wang, Jian
    Fu, Ziyi
    Li, Jun
    CANCER RESEARCH, 2018, 78 (04)
12345